Arena Pharmaceutical Inc. (ARNA) News Headlines

▮ More

Date

Headline

8/7/2019 4:04:54 PM Arena Q2 Loss Per Share Of $1.24 Vs. $0.65 Last Year

8/7/2019 4:03:59 PM EARNINGS SUMMARY: Details of Arena Pharmaceutical Inc. Q2 Earnings Report

8/7/2019 3:00:23 PM Arena Pharmaceutical Q2 19 Earnings Conference Call At 4:30 PM ET

7/25/2019 8:32:24 AM Arena Says First Subject Dosed In Phase 2 CAPTIVATE Trial Evaluating Olorinab

6/19/2019 12:30:05 PM Arena Pharma To Present At JMP Securities Conference; Webcast At 1:30 PM ET

6/17/2019 8:31:54 AM Arena Announces First Subject Dosed In ELEVATE UC 52 Global Phase 3 Trial On Etrasimod In Ulcerative Colitis

5/21/2019 7:31:29 AM Corvidia Therapeutics Appoints Preston Klassen To Board

5/17/2019 8:32:47 AM Arena Pharma Initiates Sites For ELEVATE UC Phase 3 Global Program To Evaluate Etrasimod 2 Mg

5/8/2019 4:06:14 PM Arena Pharma Q1 EPS $12.10 Vs. Loss $0.80 Year Ago

5/8/2019 4:04:05 PM EARNINGS SUMMARY: Details of Arena Pharmaceutical Inc. Q1 Earnings Report

4/10/2019 11:00:04 AM Arena Pharmaceutical Needham Healthcare Conference At 12:00 PM ET

3/8/2019 8:31:15 AM Arena Pharma Presented New Phase 2 Data For Etrasimod And Olorinab

2/26/2019 4:16:01 PM Arena Pharmaceuticals Posts Q4 Profit, Shares Up

2/26/2019 4:03:55 PM EARNINGS SUMMARY: Details of Arena Pharmaceutical Inc. Q4 Earnings Report

2/26/2019 4:02:46 PM Arena Pharmaceuticals Q4 EPS $1.35 Vs Loss $0.35 Last Year

2/26/2019 2:59:54 PM Arena Pharmaceutical Q4 18 Earnings Conference Call At 4:30 PM ET

1/24/2019 8:02:26 PM United Therapeutics Announces Closing Of License Agreement With Arena Pharmaceuticals For Ralinepag

1/10/2019 11:34:22 AM Arena Pharma. To Participate In J.P. Morgan Healthcare Conference At 12:30 PM ET

1/7/2019 8:32:37 AM Arena Reports Positive Data From Open-label Extension Of Phase 2 OASIS Trial Of Etrasimod

12/17/2018 8:30:51 AM Arena Pharmaceuticals Appoints Manmeet Soni As A Non-executive Director